Tag: Johnson & Johnson

New Analysis from Landmark CREDENCE Study Shows the Efficacy and Safety Profiles of INVOKANA® (canagliflozin) are Consistent Across Various Levels of Kidney Function

Originally Published by Johnson & Johnson Analysis shows consistent renal and cardiovascular benefit when treated with INVOKANA® even when patients had moderate to severe renal deficiency INVOKANA® is the only diabetes medicine indicated to slow the progression of diabetic nephropathy (also known as DKD) and reduce the risk of hospitalization for heart…

Johnson & Johnson Releases Inaugural You Belong: Diversity & Inclusion Impact Review

Originally Published by Johnson & Johnson Johnson & Johnson (NYSE: JNJ), the world’s largest and most broadly-based healthcare company, today published You Belong: Diversity & Inclusion Impact Review (Impact Review), which demonstrates how a strategic Diversity & Inclusion (D&I) philosophy has been a key driver of innovation and impactful business outcomes since…

Johnson & Johnson: XARELTO Helps Protect Pediatric Patients from Blood Clots in Late-Breaking Phase 3 EINSTEIN-Jr Study

Originally posted on JNJ.com The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from the Phase 3 EINSTEIN-Jr study, showing pediatric patients (aged birth to 17 years) treated with XARELTO® (rivaroxaban) had a similar low risk of recurrent venous thromboembolism (VTE) – or blood clots – and similar…